Clopidogrel Response in Essential Thrombocythemia
Part of Blood & lymphatic clinical trials.
This study tests how well a blood-thinning medication called clopidogrel works in patients with essential thrombocythemia (a condition where your body makes too many platelets). Researchers want to understand why some patients respond better to this medication than others, which could help doctors choose the best treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with essential thrombocythemia (ET) using current diagnostic criteria
- You have been taking clopidogrel 75 mg once daily for at least 3 weeks as prescribed by your doctor
- Your doctor has already tested how well you respond to clopidogrel using a specific blood test
- Your platelet count must be below 1,000,000/μL (measured three times within 2 months before joining)
- You are not taking blood thinners, other antiplatelet drugs, frequent NSAIDs, or high-dose steroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This trial tests a new injectable medicine (Peginterferon α-2b) for people with essential thrombocythemia (ET) whose disease is not controlled by hydroxyurea (HU) or who cannot tolerate HU. It aims to help lower high platelet counts and reduce the risk of clots or bleeding.
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Hear when a new Essential Thrombocythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.